Investing.com - West Pharmaceutical Services (NYSE: WST) reported second quarter EPS of $1.52, $0.22 worse than the analyst estimate of $1.74. Revenue for the quarter came in at $702.1M versus the consensus estimate of $729.36M.
Guidance
West Pharmaceutical Services sees FY 2024 EPS of $6.35-$6.65 versus the analyst consensus of $7.74.
West Pharmaceutical Services sees FY 2024 revenue of $2.87M-$2.90M versus the analyst consensus of $3.01M.
West Pharmaceutical Services's stock price closed at $323.77. It is down -10.17% in the last 3 months and down -14.67% in the last 12 months.
West Pharmaceutical Services saw 0 positive EPS revisions and 8 negative EPS revisions in the last 90 days. See West Pharmaceutical Services's stock price’s past reactions to earnings here.
According to InvestingPro, West Pharmaceutical Services's Financial Health score is "good performance".
Check out West Pharmaceutical Services's recent earnings performance, and West Pharmaceutical Services's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
WST: is this perennial leader facing new challenges?
With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is WST one of them?
Unlock ProPicks AI to find out